Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 3, 2010, Pages 579-587

  Park, Sook Ryun ^a   Kook, Myeong Cherl ^a   Choi, Il Ju ^a   Kim, Chan Gyoo ^a   Lee, Jong Yeul ^a   Cho, Soo Jeong ^a   Kim, Young Woo ^a   Ryu, Keun Won ^a   Lee, Jun Ho ^a   Lee, Jong Seok ^a   Park, Young Iee ^a   Kim, Noe Kyeong ^a  

^a National Cancer Center   (South Korea)

Author keywords

Cetuximab; Chemotherapy; Gastric cancer; K ras; Performance status; Predictor; Skin rash

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; GENE MUTATION; HUMAN; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RASH; STOMACH CANCER; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; SALVAGE THERAPY; STOMACH TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DNA MUTATIONAL ANALYSIS; EXANTHEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 75549087436     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1067-9     Document Type: Article

References (45)

1. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108 10.3322/canjclin.55.2.74 15761078
2. B Glimelius K Ekstrom K Hoffman, et al. 1997 Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 163 168 10.1023/A:1008243606668 1:STN:280:DyaK2s3kslGqug%3D%3D 9093725 (Pubitemid 27112884)
3. S Pyrhonen T Kuitunen P Nyandoto M Kouri 1995 Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587 591 1:STN:280:DyaK2M7os1ertg%3D%3D 7533517
4. AD Wagner W Grothe J Haerting G Kleber A Grothey WE Fleig 2006 Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data J Clin Oncol 24 2903 2909 10.1200/JCO.2005.05.0245 1:CAS:528:DC%2BD28XntV2gs7s%3D 16782930 (Pubitemid 46630593)
5. M Dank J Zaluski C Barone, et al. 2008 Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction Ann Oncol 19 1450 1457 10.1093/annonc/mdn166 1:STN:280:DC%2BD1cvotFCmtA%3D%3D 18558665
6. SE Al-Batran JT Hartmann S Probst, et al. 2008 Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie J Clin Oncol 26 1435 1442 10.1200/JCO.2007.13.9378 1:CAS:528:DC%2BD1cXkslKqsL8%3D 18349393
7. Y Kang WK Kang DB Shin, et al. 2006 Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results Proc Am Soc Clin Oncol 24 183s (abstr LBA4018)
8. E Van Cutsem VM Moiseyenko S Tjulandin, et al. 2006 Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 4991 4997 10.1200/JCO.2006.06.8429 17075117 (Pubitemid 46631401)
9. D Cunningham N Starling S Rao, et al. 2008 Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 36 46 10.1056/NEJMoa073149 1:CAS:528:DC%2BD1cXisFSktg%3D%3D 18172173
10. T Takehana K Kunitomo S Suzuki, et al. 2003 Expression of epidermal growth factor receptor in gastric carcinomas Clin Gastroenterol Hepatol 1 438 445 10.1016/S1542-3565(03)00219-2 1:CAS:528:DC%2BD3sXpvFSrsb0%3D 15017643 (Pubitemid 37413607)
11. A Tokunaga M Onda T Okuda, et al. 1995 Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer Cancer 75 1418 1425 10.1002/1097-0142(19950315)75:6+<1418::AID-CNCR2820751505>3. 0.CO;2-Y 1:STN:280:DyaK2M7ps1Wmuw%3D%3D 7889468
12. MA Kim HS Lee HE Lee YK Jeon HK Yang WH Kim 2008 EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number Histopathology 52 738 746 10.1111/j.1365-2559.2008.03021.x 1:CAS:528:DC%2BD1cXks1Wht70%3D 18397279 (Pubitemid 351600058)
13. J Matsubara Y Yamada Y Hirashima, et al. 2008 Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer Clin Cancer Res 14 3022 3029 10.1158/1078-0432.CCR-07-1898 1:CAS:528:DC%2BD1cXmtVCmtLc%3D 18483367
14. A Gamboa-Dominguez C Dominguez-Fonseca L Quintanilla-Martinez, et al. 2004 Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system Mod Pathol 17 579 587 10.1038/modpathol.3800085 1:CAS:528:DC%2BD2cXmsVOitro%3D 15073595 (Pubitemid 38868426)
15. JS Kim MA Kim TM Kim, et al. 2009 Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival Br J Cancer 100 732 738 10.1038/sj.bjc.6604936 1:CAS:528:DC%2BD1MXisFensLw%3D 19259093
16. FR Hirsch M Varella-Garcia PA Bunn Jr, et al. 2003 Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis J Clin Oncol 21 3798 3807 10.1200/JCO.2003.11.069 1:CAS:528:DC%2BD2cXpsVKisL8%3D 12953099 (Pubitemid 46606235)
17. RL Mahtani JS Macdonald 2008 Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract Oncologist 13 39 50 10.1634/ theoncologist.2006-0049 1:CAS:528:DC%2BD1cXivFGrt70%3D 18245011 (Pubitemid 351206695)
18. B Vincenzi G Schiavon M Silletta D Santini G Tonini 2008 The biological properties of cetuximab Crit Rev Oncol Hematol 68 93 106 10.1016/j.critrevonc. 2008.07.006 18676156
19. D Cunningham Y Humblet S Siena, et al. 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337 345 10.1056/NEJMoa033025 1:CAS:528:DC%2BD2cXlvFGitbk%3D 15269313 (Pubitemid 38944402)
20. LB Saltz NJ Meropol PJ Loehrer Sr MN Needle J Kopit RJ Mayer 2004 Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 1201 1208 10.1200/JCO.2004.10.182 1:CAS:528:DC%2BD2cXpsVGktLw%3D 14993230 (Pubitemid 41079832)
21. A Lievre JB Bachet V Boige, et al. 2008 KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 374 379 10.1200/JCO.2007.12.5906 1:CAS:528: DC%2BD1cXitVGntLc%3D 18202412 (Pubitemid 351171687)
22. A Lievre JB Bachet D Le Corre, et al. 2006 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 3992 3995 10.1158/0008-5472.CAN-06-0191 1:CAS:528:DC%2BD28XjsFSlsb0%3D 16618717
23. E Van Cutsem CH Kohne E Hitre, et al. 2009 Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 1408 1417 10.1056/NEJMoa0805019 19339720
24. C Bokemeyer I Bondarenko A Makhson, et al. 2009 Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 663 671 10.1200/JCO.2008.20.8397 1:CAS:528:DC%2BD1MXjsVCjsrk%3D 19114683
25. C Pinto F Di Fabio S Siena, et al. 2007 Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) Ann Oncol 18 510 517 10.1093/annonc/mdl459 1:STN:280:DC%2BD2s7hsVKjsA%3D%3D 17164226 (Pubitemid 46359631)
26. F Lordick S Lorenzen S Hegewisch-Becker, et al. 2007 Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer, Final results from a multicenter phase II study of the AIO upper GI study group Proc Am Soc Clin Oncol 25 204s (abstr 4526)
27. Zhang X, Xu J, Shen L et al (2009) A phase II study of cetuximab with cisplatin and capecitabine as first-line treatment in advanced gastric cancer. In: Proceedings of American society of clinical oncology 2009 gastrointestinal cancers symposium, 15-17 Jan 2009 (abstr LBA39)
28. Kim C, Lee J, Ryu M et al (2009) A prospective phase II study of cetuximab in combination with capecitabine and oxaliplatin (XELOX) in patients with metastatic and/or recurrent advanced gastric cancer. In: Proceedings of American society of clinical oncology 2009 gastrointestinal cancers symposium, 15-17 Jan 2009 (abstr 89)
29. Yeh K, Hsu C, Hsu C et al (2009) Phase II study of cetuximab plus weekly cisplatin and 24-hour infusion of high-dose 5-fluorouracil and leucovorin for the first-line treatment of advanced gastric cancer. In: Proceedings of American society of clinical oncology 2009 gastrointestinal cancers symposium, 15-17 Jan 2009 (abstr 60)
30. E Woell R Greil W Eisterer, et al. 2008 Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer: first results of a multicenter phase II trial (AGMT Gastric-2) Proc Am Soc Clin Oncol 26 662s (abstr 15587)
31. AIO Gastric group, Germany, Moehler MH, Trarbach T et al (2008) Cetuximab with irinotecan/Na-Fa/5-FU as first-line treatment in advanced gastric cancer: preliminary results of a nonrandomised multi-centre AIO phase II study. In: Proceedings of American society of clinical oncology 2008 gastrointestinal cancers symposium, 25-27 Jan 2008 (abstract 102)
32. SW Han DY Oh SA Im, et al. 2009 Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer Br J Cancer 100 298 304 10.1038/sj.bjc.6604861 1:CAS:528:DC%2BD1MXpsVSrtg%3D%3D 19127259
33. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
34. M Frattini D Balestra S Suardi, et al. 2004 Different genetic features associated with colon and rectal carcinogenesis Clin Cancer Res 10 4015 4021 10.1158/1078-0432.CCR-04-0031 1:CAS:528:DC%2BD2cXltFWmtbs%3D 15217933 (Pubitemid 38812476)
35. NC Tebbutt T Sourjina AH Strickland, et al. 2008 ATTAX2: docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophago-gastric cancer-final results of a multicentre phase II trial by the AGITG Proc Am Soc Clin Oncol 26 659s (abstr 15554)
36. B Burtness MA Goldwasser W Flood B Mattar AA Forastiere 2005 Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study J Clin Oncol 23 8646 8654 10.1200/JCO.2005.02.4646 16314626 (Pubitemid 46211507)
37. HQ Xiong A Rosenberg A LoBuglio, et al. 2004 Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial J Clin Oncol 22 2610 2616 10.1200/JCO.2004.12.040 1:CAS:528:DC%2BD2cXpsVWksLY%3D 15226328 (Pubitemid 41103748)
38. R Perez-Soler L Saltz 2005 Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23 5235 5246 10.1200/JCO.2005.00.6916 16051966 (Pubitemid 46224035)
39. SH Lee JW Lee YH Soung, et al. 2003 BRAF and KRAS mutations in stomach cancer Oncogene 22 6942 6945 10.1038/sj.onc.1206749 1:CAS:528: DC%2BD3sXnvFSgsbw%3D 14534542 (Pubitemid 37386695)
40. IJ Kim JH Park HC Kang, et al. 2003 Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers Hum Genet 114 118 120 10.1007/s00439-003-1027-0 1:CAS:528:DC%2BD3sXovFOisbk%3D 14513361 (Pubitemid 38165543)
41. A Russo V Bazan M Migliavacca, et al. 2001 DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma: results of a 5-year Gruppo Oncologico dell'Italia Meridonale (GDIM) prospective study Cancer 92 294 302 10.1002/1097-0142(20010715)92:2<294::AID-CNCR1322>3.0.CO;2-9 1:STN:280:DC%2BD3Mvhs1yrug%3D%3D 11466682 (Pubitemid 32664435)
42. J Yoo SY Park RA Robinson SJ Kang WS Ahn CS Kang 2002 ras Gene mutations and expression of Ras signal transduction mediators in gastric adenocarcinomas Arch Pathol Lab Med 126 1096 1100 1:CAS:528:DC%2BD3sXhtVyntLs%3D 12204060
43. T Hongyo GS Buzard D Palli, et al. 1995 Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy Cancer Res 55 2665 2672 1:CAS:528:DyaK2MXmtlWrt7s%3D 7780983
44. HJ Andreyev AR Norman D Cunningham JR Oates PA Clarke 1998 Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study J Natl Cancer Inst 90 675 684 10.1093/jnci/90.9.675 1:CAS:528: DyaK1cXjtlSiu7s%3D 9586664
45. Stella G, Rojas Llimpe FL, Barone C et al (2009) KRAS and BRAF mutational status and response to cetuximab combination therapy in advanced gastric cancer (GC) patients. In: Proceedings of American society of clinical oncology 2009 gastrointestinal cancers symposium, 15-17 Jan 2009 (abstr 34)